Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MitoQ 40 mg vs placebo for raised liver enzymes due to NAFLD
2010-021368-13Phase 2Terminated
- Sponsor
- Antipodean Pharmaceuticals, Inc.
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) and elevated alanine aminotransferase comparing MitoQ 40 mg with Placebo (2 arms). Primary endpoint: Percentage change in ALT level at end of treatment. Started Aug 2010; status: terminated.
02
Drugs
mitoquinone
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)elevated alanine aminotransferase
Beyond the preview
Go deeper on 2010-021368-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021368-13.